Dr. Dignam's primary research involves the design, conduct, and analysis of cancer clinical trials, including early development (phase I), pilot efficacy and safety (phase II), and definitive evaluation (phase III) trials. He is the Executive Director of the Statistics and Data Management Center for NRG Oncology, a National Cancer Institute sponsored multi-center clinical trials group with over 500 recruitment sites in North America and beyond and over 100 active clinical trials. Dr. Dignam's methodology interests include trial monitoring and early stopping rules, competing risks, hazard function estimation, and prognostic modeling. He also has engaged in and led investigations into sociodemographic factors such as race/ethnicity and BMI/obesity on cancer prognosis and treatment response. Courses taught include introductory biostatistics, clinical trials, survival analysis, and regression modeling methods.
University of Pittsburgh, Graduate School of Public Health
Pittsburgh
PhD - Biostatistics
1994
Saint Xavier College
Chicago
BA - Mathematics
1986
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time.
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2024 Jun 13; 17407745241254995.
PMID: 38872319
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2024 May 21.
PMID: 38777647
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024 Jul 10; 42(20):2377-2381.
PMID: 38759121
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024 May 03; 26(5):796-810.
PMID: 38254183
Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease.
Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease. Respir Care. 2024 Apr 22; 69(5):586-594.
PMID: 38199762
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278.
PMID: 38307806
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. Eur Urol. 2023 09; 84(3):331-340.
PMID: 37393115
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
PMID: 35753553
Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
PMID: 35050703
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021 06 20; 39(18):2037-2048.
PMID: 33939491
Co-recipient, Statistical Partnership Among Academe, Industry, and Government (SPAIG) Award
American Statistical Association
2021
Elected Fellow
Society for Clinical Trials
2019
Inducted Member
Delta Omega, National Public Health Honor Society
1991